Unfortunately, PFS was not significantly impacted by the addition of pembrolizumab to standard platinum–taxane-based therapy followed by pembrolizumab maintenance therapy in patients with incompletely resected, primarily high-grade EOC with predominantly normal germline testing, irrespective of PD-L1 tumor expression. The gene discussed is CD274; the disease is neoplasm.